Opportunity and challenge of neoadjuvant treatment in triple negative breast cancer
10.3760/cma.j.cn112139-20201116-00797
- VernacularTitle:三阴性乳腺癌新辅助治疗的机遇与挑战
- Author:
Xiaopeng HAO
1
;
Zefei JIANG
Author Information
1. 解放军总医院第一医学中心乳腺外科，北京 100853
- Keywords:
Breast Neoplasms;
Antineoplastic combined chemotherapy protocols
- From:
Chinese Journal of Surgery
2021;59(2):101-103
- CountryChina
- Language:Chinese
-
Abstract:
Triple negative breast cancer (TNBC) is a special type of breast cancer. At present, the major treatment for TNBC is chemotherapy. Neoadjuvant therapy and obtained pathology completed response could bring the TNBC patients better prognosis. The most used TNBC chemotherapy protocols are established on the basis of anthracycline and taxane. Through the thorough knowledge of molecular mechanism of TNBC, neoadjuvant therapy protocols have optimized, including the use of platinum, immune checkpoint inhibitors and poly-ADP-ribose polymerase inhibitors, and assumed positive outcome for TNBC patients.
